Pro-Dex (NASDAQ:PDEX) Price Target Raised to $52.00 at Ascendiant Capital Markets

Pro-Dex (NASDAQ:PDEX - Free Report) had its target price hoisted by Ascendiant Capital Markets from $30.00 to $52.00 in a research note issued to investors on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the medical instruments supplier's stock.

Separately, StockNews.com raised Pro-Dex from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 7th.

Pro-Dex Stock Up 10.9 %

NASDAQ PDEX traded up $4.66 during trading on Monday, reaching $47.34. 62,121 shares of the company's stock were exchanged, compared to its average volume of 13,920. The stock has a market cap of $154.33 million, a P/E ratio of 27.71 and a beta of 0.39. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 3.41. The company has a 50 day moving average price of $29.24 and a two-hundred day moving average price of $22.77. Pro-Dex has a 1 year low of $15.70 and a 1 year high of $49.94.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.11. The company had revenue of $15.03 million during the quarter. Pro-Dex had a return on equity of 16.74% and a net margin of 9.17%. On average, equities research analysts anticipate that Pro-Dex will post 1.42 EPS for the current fiscal year.

Insider Activity at Pro-Dex

In other Pro-Dex news, CFO Alisha Charlton sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $40.02, for a total transaction of $40,020.00. Following the transaction, the chief financial officer now owns 15,339 shares in the company, valued at approximately $613,866.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 47.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pro-Dex

Institutional investors have recently modified their holdings of the company. Perritt Capital Management Inc. boosted its stake in shares of Pro-Dex by 43.3% during the 1st quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier's stock worth $106,000 after acquiring an additional 1,813 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after acquiring an additional 900 shares in the last quarter. Bard Associates Inc. boosted its stake in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock worth $406,000 after acquiring an additional 2,031 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier's stock valued at $1,238,000 after buying an additional 3,067 shares in the last quarter. Hedge funds and other institutional investors own 15.28% of the company's stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.